The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Claims

18 · 3 independent · depth 5

18 granted claims

›1.independentAn isolated two-chain polypeptide comprising the amino acid sequence of SEQ ID NO. 10 or an amino acid having at least 95% sequence identity to SEQ ID…+15

›3.↳ 1A peptide conjugate comprising a carrier covalently or non-covalently linked to a polypeptide of claim 1.d2+1

›5.↳ 1A pharmaceutical composition comprising a carrier and a polypeptide of claim 1.d2+5

›7.↳ 1A polynucleotide encoding for a polypeptide of claim 1.d2

›8.↳ 1A method for preparing a polypeptide of claim 1 comprising expressing a polynucleotide encoding the polypeptide of claim 1 in a prokaryotic or eukaryo…d2+3

›12.↳ 1An isolated prokaryotic or eukaryotic host cell comprising a polynucleotide encoding a polypeptide of claim 1.d2+1

›2.independentAn isolated two-chain polypeptide comprising the amino acid sequence of SEQ ID NO. 10.

›6.independentAn isolated two-chain polypeptide consisting essentially of the amino acid sequence of SEQ ID NO. 10.

Classifications

7 codes

IPC · International Patent Classification

Section A — Human necessities

A61K47/48
A61K39/00
A61K38/48

Section C — Chemistry; metallurgy

C12N9/64

USPC · US Patent Classification

514/14.4530/384424/185.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

2.0 y

728 days filing → grant

Office actions

after a restriction

Responses

no RCE

Interviews

examiner interview summaries

Examiner

Michael Szperka

art unit 1644 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 126 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

28 Sep 2007

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 60976343	28 Sep 2007
related publication	US 20140044773 A1	13 Feb 2014

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.